Myeloma: single dose of COVID-19 vaccination provides protection for majority

A study led by The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (both London, UK) has observed that the first dose of the COVID-19 vaccine produces an antibody response in approximately 70% of myeloma patients. The findings were recently published in The Lancet Haematology. The real-world retrospective assessment study included 93 individuals with myeloma. Following the first dose of the vaccine, the team observed SARS-CoV-2 immunoglobulin G (IgG) antibodies in 56% of patients. Following further examination of blood specimens, an additional 13 patients were found to have some anti-SARS-CoV-2 antibodies. “This study is not reassuring for...